Welcome to: Rimonabant Information Source (rimonabant structure)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

Generic Acomplia, or rimonabant Anorectic against obesity drug. It is a CB1 cannabino? Receptor antagonist. Rimonabant has been found to stop eating enough desire to help people lose weight, and can also help curb other unhealthy urges, such as smoking. This is a non-control weight loss solution that in one study, people who helped overweight drop an average of 20 pounds, and was found to be very useful for patients and those suffering from obesity. How does rimonabant work? ? ав rimonabant is used to supplement diet and exercise to treat obese or overweight patients and those suffering from type 2 diabetes and abnormal levels of fat in the blood? ав rimonabant may also prevent the risk of cardiovascular disease? ав Pati? And a large waist circumference circumference (102 cm in men and 88 cm in women) will benefit from taking the drug.

Rimonabant Pricelist

Please wait while we load the price list
Life seldom gives you opportunities. If taken on time, opportunities give maximum benefits. Whenever, opportunities are not utilised on right time, they become either non beneficial or partially beneficial. You are suffering from obesity and your obesity is in its initial phase. That means, you have body mass index between 27 and 30 or slightly over than 30. If your obesity is going through this phase, then you have an opportunity for weight loss. Opportunities rarely have any name, but this time there are two popular names for such an opportunity, Rimonabant or Acomplia. Acomplia is the brand name of the medication while Rimonabant is the name of its active ingredient. Acomplia (Rimonabant), after its launch in the June 2006, has conquered a vast portion of weight loss drug market.

The growth of this class of products has not yet been realised. As a resource for developing new pharmaceutical products this area will continue to provide potential for the future, and there will be increased R&D efforts into this market. But what treatment areas will benefit? What are the products currently coming through the pipeline? Just how much market potential does this area offer? This latest report, Rimonabant: The first of the Cannabinoid blockbusters, forecasts the cannabinoid market in 2007 to generate $709 million in sales. This has grown 45% from 2006, when it was generating $386 million. The profile of the market will be raised considerably with Rimonabant, by Sanofi-Aventis, used to treat obesity and set to reach impressive sales in its first few years. Rimonabant, branded Acomplia and Zimulti (US), has now been approved for sale in all 25 countries of the European Union by the European Commission.